Immune tolerance in breast cancer

Breast Disease

Volumn 20, Issue , 2004, Pages 93-103

  Cheng, Fengdong ^a   Gabrilovich, Dmitry ^a   Sotomayor, Eduardo M ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CANCER VACCINE; CD40 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INDOLEAMINE 2,3 DIOXYGENASE; INFLUENZA VIRUS HEMAGGLUTININ; INTERLEUKIN 10; INTERLEUKIN 2; MONOCLONAL ANTIBODY; PAMIDRONIC ACID; PYROPHOSPHORIC ACID DERIVATIVE; STAT3 PROTEIN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; ZOLEDRONIC ACID;

ACTIVE IMMUNIZATION; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; BONE MARROW CELL; BONE METASTASIS; BREAST CANCER; CANCER IMMUNOTHERAPY; DENDRITIC CELL; DRUG INHIBITION; GENETIC TRANSFECTION; HUMAN; IMMUNOCOMPETENCE; IMMUNOLOGICAL TOLERANCE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; ONCOGENE C ERB; OSTEOCLAST; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; T LYMPHOCYTE;

EID: 10044235458     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-2004-20111     Document Type: Review

References (82)

1. A. Jemal et al., Cancer statistics, CA Cancer J Clin 53(1) (2003), 5-26.
2. P.E. Goss et al., A randomized trial of letrozole in post-menopausal women after five years of tamoxifen therapy for early-stage breast cancer, N Engl J Med 349(19) (2003), 1793-1802.
3. C.A. Hudis, Current status and future directions in breast cancer therapy, Clin Breast Cancer 4(Suppl 2) (2003), S70-S75.
4. D.J. Slamon et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2, N Engl J Med 344(11) (2001), 783-792.
5. L.A. Emens and E.M. Jaffee, Toward a breast cancer vaccine: work in progress, Oncology (Huntingt) 17(9) (2003), 1200-1211; discussion 1214, 1217-1218.
6. B. Yu et al., Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer, Clin Cancer Res 9(1) (2003), 285-294.
7. E.J. Fuchs et al., Cytotoxic T cells overcome BCR-ABL-mediated resistance to apoptosis, Cancer Res 55(3) (1995), 463-466.
8. A.A. Shtil et al., Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: The role of cytotoxic T lymphocytes, Blood 93(6) (1999), 1831-1837.
9. C.L. Vogel et al., Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer, J Clin Oncol 20(3) (2002), 719-726.
10. J. Horton, Trastuzumab use in breast cancer: Clinical issues, Cancer Control 9(6) (2002), 499-507.
11. D. Pardoll, T cells and tumours, Nature 411(6841) (2001), 1010-1012.
12. A.M. Vlad et al., Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: Processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells, J Exp Med 196(11) (2002), 1435-1446.
13. A. Cuenca et al., Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: Dominant role of cross-tolerance to tumor antigens, Cancer Res 63(24) (2003), 9007-9005.
14. R.A. Henderson and O.J. Finn, Human tumor antigens are ready to fly, Adv Immunol 62(1996), 217-256.
15. K.R. Jerome, N. Domenech and O.J. Finn, Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA, J Immunol 151(3) (1993), 1654-1662.
16. M.L. Disis et al., Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer, Cancer Res 54(1) (1994), 16-20.
17. M. Feuerer et al., Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow, Nat Med 7(4) (2001), 452-458.
18. D.M. Lopez et al., Cytokine production by lymphoreticular cells from mammary tumor bearing mice: The role of tumor-derived factors, Anticancer Res 16(6C) (1996), 3923-3929.
19. E.M. Sotomayor, I. Borrello and H.I. Levitsky, Tolerance and cancer: A critical issue in tumor immunology, Crit Rev Oncog 7(5-6) (1996), 433-456.
20. A.F. Ochsenbein et al., Immune surveillance against a solid tumor fails because of immunological ignorance, Proc Natl Acad Sci USA 96(5) (1999), 2233-2238.
21. V. Shankaran et al., IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity, Nature 410(6832) (2001), 1107-1111.
22. T. Boon and P. van der Bruggen, Human tumor antigens recognized by T lymphocytes, J Exp Med 183(3) (1996), 725-729.
23. P.F. Robbins and Y. Kawakami, Human tumor antigens recognized by T cells, Curr Opin Immunol 8(5) (1996), 628-636.
24. D. Pardoll, Does the immune system see tumors as foreign or self? Annu Rev Immunol 21(2003), 807-839.
25. + T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma, Eur J Immunol 26(11) (1996), 2671-2679.
26. K. Staveley-O'Carroll et al., Induction of antigen-specific T cell anergy: An early event in the course of tumor progression, Proc Natl Acad Sci USA 95(3) (1998), 1178-1183.
27. + T-cell tolerance to T-cell priming through in vivo ligation of CD40, Nat Med 5(7) (1999), 780-787.
28. P.P. Lee et al., Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients, Nat Med 5(6) (1999), 677-685.
29. R.T. Reilly et al., HER-2/neu is a tumor rejection target intolerized HER-2/neu transgenic mice, Cancer Res 60(13) (2000), 3569-3576.
30. S. Rovero et al., DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice, J Immunol 165(9) (2000), 5133-5142.
31. C. Melani et al., Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity, Blood 102(6) (2003), 2138-2145.
32. A.F. Ochsenbein et al., Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction, Nature 411(6841) (2001), 1058-1064.
33. + T cell ignorance and induction of anti-tumor immunity by peptide-pulsed APC, J Immunol 165(12) (2000), 6731-6737.
34. A.L. Marzo et al., Tumor antigens are constitutively presented in the draining lymph nodes, J Immunol 162(10) (1999), 5838-5845.
35. G.E. Plautz et A., Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors, J Immunol 165(7) (2000 , 3656-3662.
36. B.W. Robinson et al., Lack of ignorance to tumor antigens: evaluation using nominal antigen transfection and T-cell receptor transgenic lymphocytes in Lyons-Parish analysis - implications for tumor tolerance, Clin Cancer Res 7(3 Suppl) (2001), 811s-817s.
37. P. Bretscher and M. Cohn, A theory of self-nonself discrimination, Science 169(950) (1970), 1042-1049.
38. K.J. Lafferty and A.J. Cunningham, A new analysis of allogeneic interactions, Aust J Exp Biol Med Sci 53(1) (1975), 27-42.
39. G.J. Freeman et al., B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells, J Immunol 143(8) (1989), 2714-2722.
40. H. Reiser et al., Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex, Proc Natl Acad Sci USA 89(1) (1992), 271-275.
41. R.J. Noelle, CD40 and its ligand in host defense, Immunity 4(5) (1996), 415-419.
42. I. Melero et al., NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies, Cell Immunol 190(2) (1998), 167-172.
43. A.D. Weinberg, A.T. Vella and M. Croft, OX-40: Life beyond the effector T cell stage, Semin Immunol 10(6) (1998), 471-480.
44. C.D. Gimmi et al., Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation, Proc Natl Acad Sci USA 90(14) (1993), 6586-6590.
45. S. Ostrand-Rosenberg, Tumor immunotherapy: The tumor cell as an antigen-presenting cell, Curr Opin Immunol 6(5) (1994), 722-727.
46. S. Weiss and B. Bogen, B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells, Proc Natl Acad Sci USA 86(1) (1989), 282-286.
47. H.I. Levitsky et al., Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma, cells primes idiotype-specific T cells and generates potent systemic antitumor immunity, J Immunol 156(10) (1996), 3858-3865.
48. E.M. Sotomayor et al., Role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. II. Down-regulation of macrophage-mediated cytotoxicity by tumor-derived granulocyte-macrophage colony-stimulating factor, J Immunol 147(8) (1991), 2816-2823.
49. E.R. Kearney et al., Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo, Immunity 1(4) (1994), 327-339.
50. C. Kurts et al., Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells, J Exp Med 186(2) (1997), 239-245.
51. A.J. Adler et al., CD4(+) T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells [In Process Citation], J Exp Med 187(10) (1998), 1555-1564.
52. R.M. Steinman et al., The induction of tolerance by dendritic cells that have captured apoptotic cells [comment], J Exp Med 191(3) (2000), 411-416.
53. E.M. Sotomayor et al., Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression, Blood 98(4) (2001), 1070-1077.
54. A.Y. Huang et al., Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens, Science 264(5161) (1994), 961-965.
55. A. Lanzavecchia, Immunology. Licence to kill [news; comment], Nature 393(6684) (1998), 413-414.
56. F.P. Huang et al., A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes [see comments], J Exp Med 191(3) (2000), 435-444.
57. C. Scheinecker et al., Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node, J Exp Med 196(8) (2002), 1079-1090.
58. D.H. Munn et al., Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase, Science 297(5588) (2002), 1867-1870.
59. J.M. den Haan, S.M. Lehar and M.J. Bevan, CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo, J Exp Med 192(12) (2000), 1685-1696.
60. G.T. Belz et al., The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens, J Exp Med 196(8) (2002), 1099-1104.
61. F. Cheng et al., A critical role for Stat3 signaling in immune tolerance, Immunity 19(3) (2003), 425-436.
62. E.J. Fuchs and P. Matzinger, Is cancer dangerous to the immune system? Semin Immunol 8(5) (1996), 271-280.
63. T. Wang et al., Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells, Nat Med 10(1) (2004), 48-54.
64. M.R. Young, M. Newby and H.T. Wepsic, Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors, Cancer Res 47(1) (1987), 100-105.
65. Y.X. Fu et al., Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor, Cancer Res 50(2) (1990), 227-234.
66. I. Angulo et al., Involvement of nitric oxide in bone marrow-derived natural suppressor activity. Its dependence on IFN-gamma, J Immunol 155(1) (1995), 15-26.
67. B. Almand et A., Clinical significance of defective dendritic cell differentiation in cancer, Clin Cancer Res 6(5) (2000 , 1755-1766.
68. + cells, J Immunol 161 (10) (1998), 5313-5320.
69. + myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation, J Immunol 165(2) (2000), 779-785.
70. B. Almand et al., Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer, J Immunol 166(1) (2001), 678-689.
71. M. Otsuji et al., Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses, Proc Natl Acad Sci USA 93(23) (1996), 13119-13124.
72. D.I. Gabrilovich et al., Mechanism of immune dysfunction in cancer mediated by immature gr-1(+) myeloid cells, J Immunol 166(9) (2001), 5398-5406.
73. Y. Nefedova et al., Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer, J Immunol 172(1) (2004), 464-474.
74. C.T. Guy et al., Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease, Proc Natl Acad Sci USA 89(22) (1992), 10578-10582.
75. E. Di Carlo et al., Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin, Lab Invest 79(10) (1999), 1261-1269.
76. + T cell effector function and tumor-free survival in Her-2/neu-transgenic mice, J Immunol 171(4) (2003), 2161-2169.
77. P. Bansal-Pakala, A.G. Jember and M. Croft, Signaling through OX40 (CD134) breaks peripheral T-cell tolerance, Nat Med 7(8) (2001), 907-912.
78. + cytolytic T lymphocytes in vivo, Blood 103(1) (2004), 177-184.
79. G.N. Hortobagyi et al., Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group, J Clin Oncol 16(6) (1998), 2038-2044.
80. I.J. Diel et al., Reduction in new metastases in breast cancer with adjuvant clodronate treatment [see comments], N Engl J Med 339(6) (1998), 357-363.
81. D. Thiebaud et al., An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates, Calcif Tissue Int 61(5) (1997), 386-392.
82. V. Kunzmann et al., Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma, cell activity in multiple myeloma, Blood 96(2) (2000), 384-392.